Clinical trials: Sarcoma, Soft Tissue
Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
- Conditions
- Esophageal Neoplasm, Adenocarcinoma of the Gastroesophageal Junction, GastroEsophageal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04681248
- Testing
- DKN-01
- Where
- 5 sites in United States
- Sponsor
- Leap Therapeutics, Inc.
Sarcoma
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have…
- Trial name
- NCT00055952
- Testing
- exatecan mesylate
- Where
- 9 sites in United States, Canada
- Sponsor
- Daiichi Sankyo
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Solid Tumor
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
The main purpose of the dose escalation phase of the study is to determine the safety of different doses of OMX-0407. The dose expansion (phase Ib) part of the study will evaluate efficacy, safety and tolerability at a dose…
- Trial name
- NCT05826600
- Testing
- OMX-0407
- Where
- 24 sites in Belgium, France and 1 more
- Volunteers
- 68 people
- Sponsor
- iOmx Therapeutics AG
Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid…
- Trial name
- NCT00878800
- Testing
- PXD101, Doxorubicin
- Where
- 3 sites in Denmark, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Valerio Therapeutics
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET)
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One…
- Conditions
- Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
- Trial name
- NCT01222767
- Testing
- Zalypsis
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- PharmaMar
Neuroblastoma, Osteosarcoma
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).
- Conditions
- Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
- Trial name
- NCT03860207
- Testing
- Humanized 3F8 Bispecific Antibody, Blood draw
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Y-mAbs Therapeutics
Liposarcoma
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
- Trial name
- NCT02343172
- Testing
- HDM201, LEE011
- Where
- 9 sites in Canada, France and 4 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Neoplasms
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion).
- Trial name
- NCT06884618
- Testing
- RO7673396
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 405 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma…
- Conditions
- Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT03441360
- Testing
- Eribulin mesylate
- Where
- 41 sites in United States
- Volunteers
- 23 people
- Sponsor
- Eisai Inc.
Sarcoma, Ewing
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors…
- Trial name
- NCT05046314
- Testing
- TK216+Vincristin
- Where
- 8 sites in China
- Volunteers
- 15 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Solid Tumor, Sarcoma
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell…
- Conditions
- Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06975293
- Testing
- STC-15 in combination with toripalimab, STC-15 monotherapy
- Where
- 14 sites in United States
- Volunteers
- 107 people
- Sponsor
- STORM Therapeutics LTD
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Solid Tumor, Adult, Cancer
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable.
- Conditions
- Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma
- Trial name
- BETA-PRIME (NCT04673942)
- Testing
- AdAPT-001, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 140 people
- Sponsor
- EpicentRx, Inc.
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion, Infantile Fibrosarcoma
A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database
This is an observational study in which data from the past of children and young people with a specific cancer, called NTRK gene fusion positive infantile fibrosarcoma (IFS) is studied.
- Trial name
- EPI VITRAKVI (NCT05236257)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556), Standard of Care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Bayer
Sarcoma, Neutropenia
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced.
- Trial name
- NCT00035620
- Testing
- pegfilgrastim, filgrastim
- Volunteers
- 44 people
- Sponsor
- Amgen